S 2492

  • Massachusetts Senate Bill
  • 193rd Legislature (2023-2024)
  • Introduced in Senate
  • Senate
  • House
  • Governor

An Act relative to pharmaceutical access, costs and transparency

Abstract

Senate, October 30, 2023 -- The committee on Health Care Financing, to whom was referred the petitions (accompanied by bill, Senate, No. 732) of John J. Cronin for legislation to promote comprehensive transparency in the pharmaceutical industry; (accompanied by bill, Senate, No. 749) of Cindy F. Friedman, Rebecca L. Rausch, Susannah M. Whipps, Joanne M. Comerford and other members of the General Court for legislation relative to pharmaceutical access, costs and transparency; (accompanied by bill, Senate, No. 767) of Jason M. Lewis for legislation to define modest meals and refreshments in prescriber education settings; (accompanied by bill, Senate, No. 778) of Paul W. Mark for legislation to bring down the cost of prescription drugs; (accompanied by bill, Senate, No. 783) of Mark C. Montigny and Michael J. Barrett for legislation to promote transparency and prevent price gouging of pharmaceutical drug prices; (accompanied by bill, Senate, No. 784) of Mark C. Montigny for legislation relative to coverage for chronic illness; (accompanied by bill, Senate, No. 797) of Jacob R. Oliveira for legislation to bring down the cost of prescription drugs; (accompanied by bill, House, No. 619) of Nicholas A. Boldyga relative to establishing a prescription drug rebate program for seniors; (accompanied by bill, House, No. 1176) of Edward F. Coppinger and others relative to promoting comprehensive transparency in the pharmaceutical industry; (accompanied by bill, House, No. 1201) of Kate Hogan relative to the pricing of prescription drugs; (accompanied by bill, House, No. 1205) of Bradley H. Jones, Jr., and others that the Health Policy Commission and health insurers create listings of certain high cost prescription drugs and that the Attorney General require drug manufacturers to provide information to justify increases in costs; (accompanied by bill, House, No. 1206) of Bradley H. Jones, Jr., and others for an investigation by a special commission (including members of the General Court) relative to contracts between the MassHealth program and pharmaceutical benefit managers; (accompanied by bill, House, No. 1215) of John J. Lawn, Jr., and others relative to pharmacy benefit managers; (accompanied by bill, House, No. 1246) of William M. Straus relative to drug prices paid by carriers; and (accompanied by bill, House, No. 1247) of Alyson M. Sullivan-Almeida, Michael J. Soter and David F. DeCoste relative to pharmacy benefit managers reimbursements to pharmacies in the Commonwealth, reports the accompanying bill (Senate, No. 2492).

Bill Sponsors (39)

Joint Committee on Health Care Financing

     
Primary

Votes


No votes to display

Actions


Nov 15, 2023

Senate

Read second

Nov 09, 2023

Senate

Committee recommended ought to pass with an amendment, substituting a new draft, see S2499

Senate

Order relative to subject matter adopted

Senate

Placed in the Orders of the Day for Wednesday, November 15, 2023

Oct 30, 2023

Senate

New draft of S732, S749, S767, S778, S783, S784, S797, H619, H1176, H1201, H1205, H1206, H1215, H1246 and H1247

Senate

Bill reported favorably by committee and referred to the committee on Senate Ways and Means

  • Committee-Passage-Favorable
  • Referral-Committee
committee on Senate Ways and Means the committee on Senate Ways and Means

Senate

Reported from the committee on Health Care Financing

Bill Text

Bill Text Versions Format
Bill Text PDF

Related Documents

Document Format
No related documents.

Sources

Data on Open States is updated periodically throughout the day from the official website of the Massachusetts General Court.

If you notice any inconsistencies with these official sources, feel free to file an issue.